Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
GlucoSentient
AddedFeb 15, 2024
UpdatedJun 18, 2026
GlucoSentient

GlucoSentient

Pre-Seed

US-based Glucosentient, Inc, founded in 2011, specializes in manufacturing diagnostic substances.

HQ
Champaign, IL, US
Founded
2011
Overview
Compare
Fundraising
Employees
Website

Founded in 2011, GlucoSentient, Inc. is a US-based company located in Champaign, specializing in the manufacturing of in vitro and in vivo diagnostic substances. The company's core mission is to revolutionize the Blood Glucose Meter (BGM) by transforming it into a versatile diagnostic platform. GlucoSentient aims to leverage the widespread use and proven reliability of BGMs to create a powerful tool capable of measuring various health indicators, thereby enhancing diagnostic capabilities for millions of diabetics and potentially other patient groups globally.

GlucoSentient has garnered attention for its innovative approach to medical diagnostics, though specific notable affiliated people and investors are not publicly detailed. The company’s key achievement lies in its development of an enhanced BGM technology that promises to expand the utility of this common medical device beyond glucose measurement. This innovation positions GlucoSentient as a significant player in the diagnostic technology market, with the potential to impact healthcare practices and patient outcomes positively.

GlucoSentient - Quick Facts

When was GlucoSentient founded?

GlucoSentient was founded in 2011.

Where is GlucoSentient's headquarters located?

GlucoSentient's headquarters is located in Champaign, IL, US.

When was GlucoSentient's last funding round?

GlucoSentient's most recent funding round was for $900k (USD) in September 2013.

How much has GlucoSentient raised to-date?

As of Sep 16, 2013, GlucoSentient has raised a total of $1.1M (USD).

How many employees does GlucoSentient have?

GlucoSentient has 7 employees as of Feb 5, 2024.

GlucoSentient - Classification

Industry
  • Hardware
Technology
  • Analytics
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Consumers
  • Enterprise
Main Product
  • Diagnostic Substances
Tags
  • Biotech
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 15 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 541000Professional, Scientific, and Technical Services
  • 623000Nursing and Residential Care Facilities
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research